Clinical trials: Hep A
Chronic Hepatitis B
Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)
The study is to evaluate the efficacy and safety of AHB-137 in CHB participants. The total duration of the study, including screening phase, treatment phase and follow-up phase.
- Trial name
- NCT06829329
- Testing
- AHB-137, NAs
- Where
- 6 sites in China
- Volunteers
- 105 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Hepatitis C Virus Infection
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients
Hepatitis C virus (HCV) infects approximately 170 million people worldwide. The current standard- of- care therapy of chronic HCV infection is a regimen of subcutaneously administered (pegylated)-interferon-α and ribavirin for 24…
- Trial name
- NCT00255177
- Testing
- VGX-410 (Mifepristone)
- Where
- 4 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- VGX Pharmaceuticals, LLC
Hepatitis C
Study of a Novel Therapeutic Vaccine for Hepatitis C Virus
HCV002TV is a Phase I study to ascertain the safety and immunogenicity of a novel vaccine against Hepatitis C virus (HCV) in chronically infected patients.
- Trial name
- NCT01094873
- Testing
- AdCh3NSmut, Ad6NSmut
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- ReiThera Srl
Hepatocellular Carcinoma
A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation
Hepatocellular Carcinoma (HCC) recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 39 subjects with Hepatitis B virus (HBV) related HCC after liver…
- Trial name
- NCT02686372
- Testing
- TCR-T, No intervention and TCR-T (at crossover)
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Lion TCR Pte. Ltd.
Chronic Hepatitis B
Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B
This is a Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of LDT600 in pediatric and adolescent patients with chronic hepatitis B infection.
- Trial name
- NCT00907894
- Testing
- LDT600 (Telbivudine)
- Where
- 7 sites in Belgium, Germany and 2 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B
Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine
This study will assess the immunogenicity, safety and reactogenicity of GSK Biological's DTPa-HBV-IPV/ Hib vaccine as compared to GSK's DTPa-IPV/Hib vaccine co-administered with HBV according to a three-dose immunisation course…
- Trial name
- NCT00880477
- Testing
- DTPa-HBV-IPV/Hib vaccine, DTPa-IPV/Hib vaccine, EngerixTM-B
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C (HCV)
Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects
This is a proof-of-concept study which will provide data about the safety and antiviral activity of several doses of the investigational drug IDX184 given for 3 days in treatment-naive HCV genotype 1-infected subjects so that…
- Trial name
- NCT00807001
- Testing
- IDX184
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis c
Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chronic Hepatitis C (HCV)
A multicentric, observational, open-design study conducted to evaluate the efficacy and safety of Sofosdac® 400mg/60mg tablets treatment in 100 patients with chronic hepatitis C (HCV)
- Trial name
- NCT05138523
- Testing
- Sofosdac®
- Where
- 4 sites in Algeria
- Volunteers
- 99 people
- Sponsor
- Beker Laboratories
Hepatitis C Virus
Drug Interaction Oral Contraceptive Pill (OCP)
To assess the effects of BMS-650032 on Pharmacokinetics (PK) of ethinyl estradiol (EE) and norelgestromin (NGMN) in healthy female subjects
- Trial name
- NCT01063023
- Testing
- Ortho Tri-Cyclen®, BMS-650032
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV/HCV Coinfection
Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)
This is an uncontrolled, open-label, Phase III trial of peginterferon alfa-2a (Pegasys) in participants coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV).
- Trial name
- NCT02762383
- Testing
- Peginterferon Alfa-2
- Where
- 10 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic (CHB)
Study of AHB-171 in Chronic Hepatitis B Participants
The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated…
- Trial name
- NCT07630727
- Testing
- AHB-171 Injection
- Where
- 10 sites in China
- Volunteers
- 138 people
- Sponsor
- Ausper Biopharma Co., Ltd.
HCV Infection
Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol
This study will evaluate the effect of sofosbuvir (SOF)/velpatasvir (VEL)/voxilaprevir (VOX) fixed-dose combination (FDC) + voxilaprevir on the pharmacokinetics (PK) of a representative hormonal contraceptive medication…
- Trial name
- NCT02533427
- Testing
- SOF/VEL/VOX, VOX, Norgestimate/ethinyl estradiol
- Where
- New Zealand
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis C
Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
Patients with chronic hepatitis genotype 1b, who are intolerant or ineligible to Interferon alfa therapy with or without Ribavirin, will be treated for 24 weeks with Daclatasvir (DCV) Dual regimen (= Daclatasvir + Asunaprevir)…
- Trial name
- NCT01995266
- Testing
- Asunaprevir, Daclatasvir
- Where
- 38 sites in China, South Korea and 1 more
- Volunteers
- 218 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial
The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with BMS-914143 and achieved sustained virologic response
- Trial name
- NCT01525810
- Testing
- Peginterferon Lambda-1a (BMS-914143)
- Where
- 75 sites in United States, Argentina and 17 more
- Volunteers
- 218 people
- Sponsor
- Bristol-Myers Squibb
Diphtheria, Tetanus
A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults
This is a single-center, randomized, active-controlled, parallel-group, open-label, phase I study to evaluate safety and immunogenicity of single injection of LBVD or Eupenta co-administered with Imovax Polio in healthy adults.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT03208101
- Testing
- DTP-HepB-IPV-Hib vaccine, DTP-HepB-Hib vaccine & IPV
- Where
- South Korea
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- LG Chem
Hepatitis A
The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children
The purpose of this follow-up study is to evaluate the five-year immune persistence of one injection of inactivated and attenuated alive hepatitis A vaccine in healthy children.
- Trial name
- NCT02002065
- Testing
- Inactivated HAV vaccine, Attenuated alive HAV vaccine
- Where
- China
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Hepatitis C
A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults
To evaluate the safety, tolerability and pharmacokinetics of ABT-072 in healthy volunteers and its anti-viral activity in HCV infected subjects.
- Trial name
- NCT00752687
- Testing
- ABT-072
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Abbott
Hepatitis C, Chronic
PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b
This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) or…
- Trial name
- NCT01066793
- Testing
- Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®]
- Where
- 100 sites in Belgium, Ireland and 2 more
- Volunteers
- 2,343 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Virus Genotype 1
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I
Based on 12-week on-treatment data, at least 1 dose of BMS-824393 can be identified which is safe, well tolerated, and has sufficient antiviral activity to progress to late stage clinical trials when combined with pegIFNα/RBV for…
- Trial name
- NCT01142700
- Testing
- BMS-824393, Peginterferon Alpha-2a, Ribavirin
- Where
- 11 sites in United States
- Sponsor
- Bristol-Myers Squibb
Hepatitis B
Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder
The purpose of this study is to assess the long-term persistence of immunity to hepatitis B in adolescents aged 15-16 years who were vaccinated with Engerix™-B Kinder in infancy.
- Trial name
- NCT01847430
- Testing
- Engerix™-B Kinder
- Where
- 10 sites in Germany
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.